News Conference News ISC 2026 OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding Todd Neale February 09, 2026
News Conference News ESOC 2025 Simple, Phone-Based Strategy Improves BP Control in Stroke Survivors Todd Neale June 02, 2025
News Conference News VIVA 2024 It’s Been 1 Year Since Medicare’s NCD for Carotid Stenting: What Now? L.A. McKeown November 14, 2024
News Daily News Dramatic LDL Drops Seen in PAD Patients With Team-Based Care L.A. McKeown June 18, 2024
News Daily News Reduction in BP Drives Treatment Preference for Hypertensive Patients Michael O'Riordan December 20, 2022
News Daily News PCI and CABG Are Complementary Options for Left Main CAD, Say Experts Michael O'Riordan April 27, 2022
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News TCT 2021 Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints Todd Neale November 04, 2021
News Conference News ACC 2020 ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up Shelley Wood March 30, 2020
News Daily News New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration L.A. McKeown December 18, 2018
News Conference News CRT 2018 Ticagrelor: Better Platelet Blockade Post-TAVR? Michael O'Riordan March 07, 2018
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for October 2017 Shelley Wood October 29, 2017
News Conference News ESC 2017 Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death Yael L. Maxwell September 01, 2017
News Daily News Anticoagulation in Pregnant Women With Mechanical Heart Valves: A Balancing Act Caitlin E. Cox May 31, 2017
News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016
News Industry News New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control March 01, 2016